Upstart Mind Cure (CSE:MCUR) Set To Disrupt $300 Billion Industry
“May revolutionize mental health care” - Fortune
The mental healthcare industry is ripe for innovation.
And companies like Mind Cure (CSE: MCUR), which recently completed its IPO, are set to lead the way.
Recently top medical researchers have returned to an old idea to addiction, depression, PTSD, and more.
And, judging by the climb in Mind Cure's shares, it's working.
Early indications from clinical research say it could, as Fortune Magazine says, “revolutionize mental health care.”1
Top Silicon Valley, venture capital, and biotech investors are getting behind it in a big way.
In the last few months we’ve seen major investments of $30 million2, $80 million3, and a planned $100 million+ later this year.4
Mind Cure CSE:MCUR is positioning itself at being at the front of it all. And with its IPO, it’s poised to take a giant step forward in this race.
Consider a recent article from the Wall Street Journal – the investors paper of record. It reported that this new class of psychedelic-based drugs “can help alleviate depression, anxiety and addiction.”5
Fortune magazine – another seminal source for investors looking to maximize their returns – declared, “Psychedelic drugs may revolutionize mental health care.”6
And NBC News recently proclaimed, “Therapeutic ‘trips’ may someday bring relief from addiction, anxiety, depression — and even the fear of death.”7
And its not just the press either.
Academia is also fully on board. Top researchers at Yale, Johns Hopkins, University of North Carolina,8 and many other top universities worldwide are paving the way forward for an entirely new class of drugs that can change the way we live, how well we live – and how long we live.
The U.S. government has even started researching the remarkable power of psychedelics.
In June of 2020 the Department of Defense’s Defense Advanced Research Projects Agency (DARPA) announced it would invest $26.9 million into researching medicinal applications for psychedelic drugs.
DARPA said its psychedelics research “aims to create new medications to effectively and rapidly treat depression, anxiety, and substance abuse without major side effects.”9
The rise of psychedelics is here.
There are years of growth ahead and, if psychedelics are as disruptive as some of the world’s top investors believe, there is exponential potential for early investors.
That’s where Mind Cure (CSE:MCUR) comes in because it’s just starting its growth trajectory.
READ: The Three Hottest Psychedelic Stocks That Every Investor Should Research
Mind Cure is a mental health and wellness company focused on identifying, developing and commercializing products that enhance mental health and wellness, ease suffering and increase productivity in the midst of global mental health crisis.10
The company is focusing on the five largest aspects of the psychedelic-derived research market.
Mind Cure has targeted nootropics as a beachhead in the massive global nutritional health industry.
A nootropic is a drug or supplement used to enhance cognitive function and fit right into Mind Cure’s aggressive growth strategy.
Mind Cure’s products will be a functional mushroom powder sold under the Moombeam brand. Within the Moonbeam brand there will be targeted products offering specific benefits to consumers with Moonbeam Energy, Focus, and Protection types and we be a quick path to revenues.
Mind Cure has targeted broad range of outlets for distribution throughout the U.S and Canada.
The Company has received its Canadian Health Product Authorization Numbers (HPN) s, which authorizes the sale of natural products like functional mushrooms and will be ramping up sales efforts through multiple channels.
The first physical distribution point is through Body Energy Club franchises. The Body Energy Club has 17 locations in Canada and the United States.
After that, Mind Cure has announced it will be targeting online sales and distribution directly to consumers and through Amazon, Google Shopping, eBay, Bonanza, and Walmart Marketplace.
The total market for just the functional mushrooms is $23 billion per year and growing.
Mind Cure will be researching new products that align with and complement its Nootropic Formulations above.
This strategy of research and developing new products allows Mind Cure to leverage its building customer base and its early-mover advantages in the functional mushroom and broader nootropic sectors.
Clinical Research Technology
Clinical biotech researchers will tell you one of the biggest problems in researching and developing treatments of any kind for mental health is tracking and measurement of the efficacy of the treatment.
Mind Cure has developed user-friendly software to much more actively that targeted at solving that problem.
Formulation and Supply
Mind Cure is currently investigating and developing potential plans including the capital requirements, economics, and timelines for manufacturing, importing, and supplying traditional and novel psychoactive compounds (NPS).
These could include: LSD, NPS’s, MDMA, Ketamine, Psilocybin DMT
Mind Cure may be able to take the information it learns from customer feedback, academic research, and other sources and apply investigate to clinical research for the eventual development and targeting of new product candidates.
In the end, Mind Cure is a company structured in a way to ride the psychedelics boom in multiple ways.
And the timing of Mind Cure’s emergence is as good as it gets.
“Mind Cure believes the mental health space is ripe for innovation, and investment that could lead to major disruption in how mental health is treated.”Mind Cure 2020
Consider Investing In Psychedelics Now
Again, the mental health care industry is long overdue for major innovation.
Anti-depressants, many developed in the middle of the last century, have consistently proven to not be the most effective treatments or even possibly counterproductive in many cases.
Psychedelics have the potential to be the disruptive force that shakes up the entire mental health sector.
And now novel psychedelic treatments have attracted the financial backing of some of the biggest money investors in the world and can truly advance clinical research in psychedelics targeted at the most promising solutions.
That final change – the infusion of capital – will change everything for all facets of the psychedelics industry.
Companies like Mind Cure (MCUR) may be positioned to ride the psychedelics boom all the way to the top too.
All the best,
Psychedelic Stock Watch Team
10 Mind Cure Prospectus
The content on Psychedelic Stock Watch is not personalized investment advice. Our employees strive to give smart, stimulating commentary, but are not licensed to address or give advice on individual investment situations. Nothing you receive from Psychedelic Stock Watch should be considered personal investment advice. Any investments recommended by Psychedelic Stock Watch should only be made after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. All investments carry risk of significant loss.
Please see full disclaimers at https://psychedelicstockwatch.com/ applicable to all content provided by PSW , wherever published or re-published: https://psychedelicstockwatch.com/statements-policies
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. PsychedelicStockWatch.com (PSW) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.
PSW receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to PSW and may hire additional publishers or advertisers on behalf of the issuer. PSW retains any excess sums after expenses as its compensation. PSW may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus PSW and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.
PSW and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; PSW is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.
This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or PSW or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at http://www.sec.gov where readers can review all public filings submitted by the issuer. PSW is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.